156 related articles for article (PubMed ID: 28223795)
1. Nanoparticle-based hyperthermia distinctly impacts production of ROS, expression of Ki-67, TOP2A, and TPX2, and induction of apoptosis in pancreatic cancer.
Ludwig R; Teran FJ; Teichgraeber U; Hilger I
Int J Nanomedicine; 2017; 12():1009-1018. PubMed ID: 28223795
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors - quantitative detection of the Ki-67, TPX2, TOP2A, and hTERT telomerase subunit mRNA levels to determine proliferation activity and a potential for aggressive biological behavior.
Kalfusova A; Hilska I; Krskova L; Kalinova M; Linke Z; Kodet R
Neoplasma; 2016; 63(3):484-92. PubMed ID: 26952515
[TBL] [Abstract][Full Text] [Related]
3. High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area.
Kossatz S; Ludwig R; Dähring H; Ettelt V; Rimkus G; Marciello M; Salas G; Patel V; Teran FJ; Hilger I
Pharm Res; 2014 Dec; 31(12):3274-88. PubMed ID: 24890197
[TBL] [Abstract][Full Text] [Related]
4. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery.
Kossatz S; Grandke J; Couleaud P; Latorre A; Aires A; Crosbie-Staunton K; Ludwig R; Dähring H; Ettelt V; Lazaro-Carrillo A; Calero M; Sader M; Courty J; Volkov Y; Prina-Mello A; Villanueva A; Somoza Á; Cortajarena AL; Miranda R; Hilger I
Breast Cancer Res; 2015 May; 17(1):66. PubMed ID: 25968050
[TBL] [Abstract][Full Text] [Related]
5. The phenotype of target pancreatic cancer cells influences cell death by magnetic hyperthermia with nanoparticles carrying gemicitabine and the pseudo-peptide NucAnt.
Sanhaji M; Göring J; Couleaud P; Aires A; Cortajarena AL; Courty J; Prina-Mello A; Stapf M; Ludwig R; Volkov Y; Latorre A; Somoza Á; Miranda R; Hilger I
Nanomedicine; 2019 Aug; 20():101983. PubMed ID: 30940505
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.
Miwa T; Kokuryo T; Yokoyama Y; Yamaguchi J; Nagino M
Cancer Med; 2015 Jul; 4(7):1091-100. PubMed ID: 25914189
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
[TBL] [Abstract][Full Text] [Related]
10. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
11. [Effects of magnetic thermotherapy mediated by magnetic nanocomposite PEG-APTESMNP on proliferation of liver cancer cells].
Zheng Q; Gao P; Li X; Li H
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Aug; 39(8):891-897. PubMed ID: 31511207
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
Heestand GM; Schwaederle M; Gatalica Z; Arguello D; Kurzrock R
Eur J Cancer; 2017 Sep; 83():80-87. PubMed ID: 28728050
[TBL] [Abstract][Full Text] [Related]
13. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.
Malhotra S; Lapointe J; Salari K; Higgins JP; Ferrari M; Montgomery K; van de Rijn M; Brooks JD; Pollack JR
PLoS One; 2011; 6(5):e20293. PubMed ID: 21629784
[TBL] [Abstract][Full Text] [Related]
14. TOPBP1 recruits TOP2A to ultra-fine anaphase bridges to aid in their resolution.
Broderick R; Nieminuszczy J; Blackford AN; Winczura A; Niedzwiedz W
Nat Commun; 2015 Mar; 6():6572. PubMed ID: 25762097
[TBL] [Abstract][Full Text] [Related]
15. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
16. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
17. TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway.
Pei YF; Yin XM; Liu XQ
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):197-207. PubMed ID: 29045811
[TBL] [Abstract][Full Text] [Related]
18. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
19. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways.
Yang Z; Liu Y; Shi C; Zhang Y; Lv R; Zhang R; Wang Q; Wang Y
Oncol Rep; 2017 Feb; 37(2):1011-1019. PubMed ID: 28075472
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation.
Baumann KW; Baust JM; Snyder KK; Baust JG; Van Buskirk RG
Technol Cancer Res Treat; 2017 Aug; 16(4):393-405. PubMed ID: 27340260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
